glp-1 receptor agonist drugs list Comparing Ozempic, Wegovy and Other Trends in the Development of

Third, GLP-1 receptor agonists (particularly the shorter-acting agents) delay gastric emptying, thus delaying carbohydrate absorption and promoting satiety

2014;8(262275):e9

However, it is not clear whether these ameliorations in bone strength result from activation of skeletal GLP-1 receptors or whether it requires extra-skeletal receptors as observed for the GIP/GIPR pathway [866]

In the SUSTAIN 8 study, patients with T2DM exhibited a lean mass decrease of 2.3 kg alongside a total weight loss of 5.3 kg, resulting in 43.4% of weight loss attributable to lean mass, while the ratio of lean mass to total mass increased by 1.2% from the baseline [111]

Wegovy is available at a higher dosage than Ozempic, and in clinical trials, it has been more common for people to report side effects while using it